Statistical analyses Statistical analyses were performed using Stata SE 15.0 for Microsoft Windows (Stata Corp LP, Texas, USA)
Devaiah BN, Mu J, Akman B, et al
The foundational characterisation comes from Raun et al., 1998, who described ipamorelin as "the first selective growth hormone secretagogue." In the taxonomy of research peptides, ipamorelin therefore sits between the older, less selective compounds such as GHRP-2 and GHRP-6 on one side and the GHRH analogues such as CJC-1295 or tesamorelin on the other
Tajiri, K
Phase 3 trials are underway, and a realistic approval window is late 2026 at the earliest, more likely 2027
The participants taking Wegovy, on the other hand, experienced more than double the weight loss, at 15.8% on average